The partnership will use Skyhawk’s proprietary SkySTAR technology to invent small molecules that can correct RNA splicing, which has been linked to a wide variety of disease-causing mutations. Takeda will have exclusive license to develop and commercialize therapies targeting multiple neurodegenerative diseases using those small molecules.
“Takeda is deeply committed to pursuing innovative approaches that target central nervous system diseases with no available or effective treatments,” Emiliangelo Ratti, head of Takeda’s neuroscience therapeutic area, said in a statement. “Skyhawk’s novel approach in correcting RNA expression will complement our expertise in small molecule science and may improve our chances of targeting neurological diseases that have previously been considered undruggable.”
More articles about health IT:
NIH ‘All of Us’ research program unveils interactive data browser
How single sign-on within EHRs can save clinicians time, reduce hospital costs & improve patient care
Startup using CRISPR to treat heart disease earns $58.5M in Series A funding
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
